Company will highlight ROSA™ Brain and recently FDA cleared ROSA™ Spine systems at largest meeting of orthopaedic surgeons
Montpellier, France, February 29, 2016 – MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, today announced its participation at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, being held March 1-5 in Orlando, Florida.
The Annual Meeting is the AAOS' premier event and draws more than 30,000 participants, including Academy Fellows, members, international guests, allied health professionals, and exhibitors. During the conference, at booth #3709, Medtech will be providing hands-on demonstrations of the recently FDA cleared ROSA™ Spine system and its ROSA™ Brain system.
Bertin Nahum, CEO and Founder of Medtech, commented, “As one of the most prominent global meetings of orthopaedic surgeons, AAOS provides a significant opportunity to highlight our recently FDA cleared ROSA Spine system to potential customers from the U.S. and international markets.”
Medtech's ROSA™ robotic surgery system is designed for minimally invasive surgery. ROSA™ Brain received FDA clearance in 2012, and there are currently 31 of these systems installed in North American facilities. ROSA™ Spine received FDA clearance in January 2016. However, the robot has been in use in Europe since receiving the CE mark in 2014.
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués
Full and original press release in PDF:
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|MEDTECH||Euronext Paris||50.00 (c)||0.00%||0|